284 related articles for article (PubMed ID: 31015204)
1. Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling.
Gomez-Soler M; Petersen Gehring M; Lechtenberg BC; Zapata-Mercado E; Hristova K; Pasquale EB
J Biol Chem; 2019 May; 294(22):8791-8805. PubMed ID: 31015204
[TBL] [Abstract][Full Text] [Related]
2. Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase.
Ferluga S; Hantgan R; Goldgur Y; Himanen JP; Nikolov DB; Debinski W
J Biol Chem; 2013 Jun; 288(25):18448-57. PubMed ID: 23661698
[TBL] [Abstract][Full Text] [Related]
3. A small peptide promotes EphA2 kinase-dependent signaling by stabilizing EphA2 dimers.
Singh DR; Pasquale EB; Hristova K
Biochim Biophys Acta; 2016 Sep; 1860(9):1922-8. PubMed ID: 27281300
[TBL] [Abstract][Full Text] [Related]
4. An ephrin mimetic peptide that selectively targets the EphA2 receptor.
Koolpe M; Dail M; Pasquale EB
J Biol Chem; 2002 Dec; 277(49):46974-9. PubMed ID: 12351647
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationship analysis of peptides targeting the EphA2 receptor.
Mitra S; Duggineni S; Koolpe M; Zhu X; Huang Z; Pasquale EB
Biochemistry; 2010 Aug; 49(31):6687-95. PubMed ID: 20677833
[TBL] [Abstract][Full Text] [Related]
6. Architecture of Eph receptor clusters.
Himanen JP; Yermekbayeva L; Janes PW; Walker JR; Xu K; Atapattu L; Rajashankar KR; Mensinga A; Lackmann M; Nikolov DB; Dhe-Paganon S
Proc Natl Acad Sci U S A; 2010 Jun; 107(24):10860-5. PubMed ID: 20505120
[TBL] [Abstract][Full Text] [Related]
7. Ligand recognition by A-class Eph receptors: crystal structures of the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex.
Himanen JP; Goldgur Y; Miao H; Myshkin E; Guo H; Buck M; Nguyen M; Rajashankar KR; Wang B; Nikolov DB
EMBO Rep; 2009 Jul; 10(7):722-8. PubMed ID: 19525919
[TBL] [Abstract][Full Text] [Related]
8. Pinpointed Stimulation of EphA2 Receptors via DNA-Templated Oligovalence.
Möser C; Lorenz JS; Sajfutdinow M; Smith DM
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404153
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor.
Tognolini M; Incerti M; Hassan-Mohamed I; Giorgio C; Russo S; Bruni R; Lelli B; Bracci L; Noberini R; Pasquale EB; Barocelli E; Vicini P; Mor M; Lodola A
ChemMedChem; 2012 Jun; 7(6):1071-83. PubMed ID: 22529030
[TBL] [Abstract][Full Text] [Related]
10. The SAM domain inhibits EphA2 interactions in the plasma membrane.
Singh DR; Ahmed F; Paul MD; Gedam M; Pasquale EB; Hristova K
Biochim Biophys Acta Mol Cell Res; 2017 Jan; 1864(1):31-38. PubMed ID: 27776928
[TBL] [Abstract][Full Text] [Related]
11. Structure-Based Design of Novel EphA2 Agonistic Agents with Nanomolar Affinity in Vitro and in Cell.
Gambini L; Salem AF; Udompholkul P; Tan XF; Baggio C; Shah N; Aronson A; Song J; Pellecchia M
ACS Chem Biol; 2018 Sep; 13(9):2633-2644. PubMed ID: 30110533
[TBL] [Abstract][Full Text] [Related]
12. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors.
Noberini R; Koolpe M; Peddibhotla S; Dahl R; Su Y; Cosford ND; Roth GP; Pasquale EB
J Biol Chem; 2008 Oct; 283(43):29461-72. PubMed ID: 18728010
[TBL] [Abstract][Full Text] [Related]
13. UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations.
Hassan-Mohamed I; Giorgio C; Incerti M; Russo S; Pala D; Pasquale EB; Zanotti I; Vicini P; Barocelli E; Rivara S; Mor M; Lodola A; Tognolini M
Br J Pharmacol; 2014 Dec; 171(23):5195-208. PubMed ID: 24597515
[TBL] [Abstract][Full Text] [Related]
14. Restriction of receptor movement alters cellular response: physical force sensing by EphA2.
Salaita K; Nair PM; Petit RS; Neve RM; Das D; Gray JW; Groves JT
Science; 2010 Mar; 327(5971):1380-5. PubMed ID: 20223987
[TBL] [Abstract][Full Text] [Related]
15. Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists.
Callegari D; Pala D; Scalvini L; Tognolini M; Incerti M; Rivara S; Mor M; Lodola A
Molecules; 2015 Sep; 20(9):17132-51. PubMed ID: 26393553
[TBL] [Abstract][Full Text] [Related]
16. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.
Wykosky J; Debinski W
Mol Cancer Res; 2008 Dec; 6(12):1795-806. PubMed ID: 19074825
[TBL] [Abstract][Full Text] [Related]
17. Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction.
Pala D; Castelli R; Incerti M; Russo S; Tognolini M; Giorgio C; Hassan-Mohamed I; Zanotti I; Vacondio F; Rivara S; Mor M; Lodola A
J Chem Inf Model; 2014 Oct; 54(10):2621-6. PubMed ID: 25289483
[TBL] [Abstract][Full Text] [Related]
18. Target hopping as a useful tool for the identification of novel EphA2 protein-protein antagonists.
Tognolini M; Incerti M; Pala D; Russo S; Castelli R; Hassan-Mohamed I; Giorgio C; Lodola A
ChemMedChem; 2014 Jan; 9(1):67-72. PubMed ID: 24115725
[TBL] [Abstract][Full Text] [Related]
19. Receptor-binding domain of ephrin-A1: production in bacterial expression system and activity.
Nekrasova OV; Sharonov GV; Tikhonov RV; Kolosov PM; Astapova MV; Yakimov SA; Tagvey AI; Korchagina AA; Bocharova OV; Wulfson AN; Feofanov AV; Kirpichnikov MP
Biochemistry (Mosc); 2012 Dec; 77(12):1387-94. PubMed ID: 23244735
[TBL] [Abstract][Full Text] [Related]
20. A computational and laboratory approach for the investigation of interactions of peptide conjugated natural terpenes with EpHA2 receptor.
Goncalves BG; Banerjee IA
J Mol Model; 2023 Jun; 29(7):204. PubMed ID: 37291458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
